Illumina, Inc. (NASDAQ:ILMN) Shares Bought by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. lifted its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 426.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,460 shares of the life sciences company's stock after acquiring an additional 12,521 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in Illumina were worth $2,123,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Trivant Custom Portfolio Group LLC increased its stake in Illumina by 166.7% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company's stock worth $27,000 after buying an additional 125 shares during the period. Wetzel Investment Advisors Inc. purchased a new position in Illumina in the 4th quarter worth about $37,000. Massmutual Trust Co. FSB ADV increased its stake in Illumina by 86.8% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company's stock worth $39,000 after buying an additional 132 shares during the period. Gradient Investments LLC increased its stake in Illumina by 375.0% in the 4th quarter. Gradient Investments LLC now owns 285 shares of the life sciences company's stock worth $40,000 after buying an additional 225 shares during the period. Finally, MeadowBrook Investment Advisors LLC purchased a new position in Illumina in the 4th quarter worth about $42,000. Institutional investors own 89.42% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ILMN shares. Stephens reissued an "overweight" rating and set a $170.00 target price on shares of Illumina in a research report on Wednesday, July 10th. Scotiabank cut their target price on shares of Illumina from $185.00 to $176.00 and set a "sector outperform" rating on the stock in a research report on Monday, May 6th. Citigroup raised shares of Illumina from a "neutral" rating to a "buy" rating and set a $140.00 target price on the stock in a research report on Wednesday, July 10th. TD Cowen cut their target price on shares of Illumina from $140.00 to $122.00 and set a "hold" rating on the stock in a research report on Thursday, June 6th. Finally, OTR Global reissued a "mixed" rating on shares of Illumina in a research report on Wednesday, March 20th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $158.57.

Illumina Stock Performance

ILMN stock traded up $0.47 during trading on Monday, reaching $116.56. The company had a trading volume of 1,408,833 shares, compared to its average volume of 2,169,591. The firm has a 50-day simple moving average of $108.90 and a 200-day simple moving average of $125.20. The company has a market cap of $18.57 billion, a price-to-earnings ratio of -14.30 and a beta of 1.15. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.36 and a current ratio of 1.75. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $195.64.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. The company had revenue of $1.08 billion during the quarter, compared to analysts' expectations of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. Illumina's revenue for the quarter was down 1.0% on a year-over-year basis. During the same period last year, the business earned $0.08 EPS. As a group, sell-side analysts expect that Illumina, Inc. will post 0.98 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.